Emergent BioSolutions to acquire Adapt Pharma
Adapt Pharma, maker of Narcan Nasal Spray, has entered into a definitive agreement with Emergent BioSolutions to be acquired, the companies announced this week. No terms were disclosed, but the companies said that all employees and facilities from Adapt would be retained.
“I am delighted that this transaction will bring Adapt and Emergent together to focus on critical treatments within the opioid crisis – one of the leading public health issues of our time,” Adapt Pharma CEO and chairman Seamus Mulligan said With a shared mission of protecting lives from public health threats, I am confident that our combined expertise and resources will accelerate access to Narcan Nasal Spray through investments in public awareness and manufacturing capacity while maintaining a responsible pricing approach. It will also allow us to progress Adapt’s R&D pipeline of additional opioid overdose and addiction treatment options”
The companies noted that Adapt Pharma is focused on combating opioid overdose and Emergent focuses on developing, supplying and providing medical countermeasures to public health threats and emerging infectious diseases.
“The acquisition of Adapt Pharma, and with it Narcan Nasal Spray, is directly in line with our mission — to protect and enhance life,” Emergent BioSolutions CEO Daniel Abdun-Nabi said. “By leveraging Emergent’s core competencies and 20-year track record as a trusted partner to the Federal government, and Adapt’s demonstrated success with state and local government, first responder, and commercial channels, we expect to combine efforts to address the opioid overdose epidemic.”
“I am delighted that this transaction will bring Adapt and Emergent together to focus on critical treatments within the opioid crisis – one of the leading public health issues of our time,” Adapt Pharma CEO and chairman Seamus Mulligan said With a shared mission of protecting lives from public health threats, I am confident that our combined expertise and resources will accelerate access to Narcan Nasal Spray through investments in public awareness and manufacturing capacity while maintaining a responsible pricing approach. It will also allow us to progress Adapt’s R&D pipeline of additional opioid overdose and addiction treatment options”
The companies noted that Adapt Pharma is focused on combating opioid overdose and Emergent focuses on developing, supplying and providing medical countermeasures to public health threats and emerging infectious diseases.
“The acquisition of Adapt Pharma, and with it Narcan Nasal Spray, is directly in line with our mission — to protect and enhance life,” Emergent BioSolutions CEO Daniel Abdun-Nabi said. “By leveraging Emergent’s core competencies and 20-year track record as a trusted partner to the Federal government, and Adapt’s demonstrated success with state and local government, first responder, and commercial channels, we expect to combine efforts to address the opioid overdose epidemic.”